Færch, Louise
Novo Nordisk (Denmark)
2 papers on CoChat
Most cited papers
- Verified
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 1,419
- Verified
Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes
Færch, L. H., Thorsteinsson, B., Tarnow, L., Holst, J. J., Kjær, T., Kanters, J., Larroude, C., Dela, F., & Pedersen-Bjergaard, U. (2015) · Journal of the Renin-Angiotensin-Aldosterone System
Diabetes Management and ResearchRenin-Angiotensin System Studies
Cited by 8
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free